Please provide your email address to receive an email when new articles are posted on . Vuity, an eye drop for the treatment of presbyopia, is now available, according to a press release from AbbVie. ...

A Prescription Drug User Fee Act target date of January 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Brimochol ™ ...

Please provide your email address to receive an email when new articles are posted on . The submission is supported by positive data from the phase 3 BRIO-I and BRIO-II studies. If approved, Brimochol ...

The US Food and Drug Administration for the first time has approved an eye drop to treat presbyopia, also known as age-related blurry near vision, in adults. Pilocarpine HCl ophthalmic solution 1.25% ...

EDOF technology, previously used in intraocular lenses, is now available in contact lenses, offering significant improvements ...

Deseyne ® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia Correction ...

The FDA approved aceclidine 1.44% ophthalmic solution (Vizz) for adults with presbyopia, or age-related blurred near vision, maker Lenz Therapeutics announced on Thursday. It marks the first ...

The phase 3 NEAR-1 and NEAR-2 trials included 613 patients aged 45 to 64 years with presbyopia. Positive results were announced from two phase 3 trials evaluating the efficacy and safety of CSF-1, a ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

A new once-a-day eye drop designed to improve blurry vision in adults is now commercially available in the United States. The product, known as VIZZ 1.44%, offers a nonsurgical option for people ...

The FDA approved pilocarpine hydrochloride ophthalmic solution (Qlosi) for adults with presbyopia, according to a statement from Orasis Pharmaceuticals. The approval allows for daily or as-needed use, ...

Company to host conference call on Tuesday, October 29, 2019 at 5:00 pm ET NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical ...